Combination Targeted Therapy

• 6483 · PDF Convergent CDK4/6 and PI3K/mTOR pathway hyperactivation defines a targetable axis in osteosarcoma across RB1-proficient and RB1-deficient contexts Lauren K. Stevens, M. Reza Saadatzadeh, Farinaz Barghi, Erika A. Dobrota, Harlan E. Shannon, Rada Malko, Ryli Justice, Christopher Davis, Keiko Kreklau, Melissa A. Trowbridge, Kathy Coy, Felicia M. Kennedy, Anthony L. Sinn, Kyle W. Jackson, George Sandusky, L. Daniel Wurtz, Christopher D. Collier, Dana Mitchell, Ed Greenfield, Emma H. Doud, Amber L. Mosley, Steven P. Angus, Pankita H. Pandya, Karen E. Pollok
• 6484 · PDF Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis in prostate cancer Feiyu Chen, Qidong Li, Qianlin Gu, Javier Leo, Xin Liang, Naayaa Mehta, Yin Wang, Francisco R. Saenz, Maya M. Phillips, Wei Shi, Chenling Meng, Jie Zhang, Boyi Gan, Di Zhao
• 6485 · PDF Combination of the GCN2 activator HC-7366 with VEGFR-TKI results in greater efficacy than VEGFR-TKI alone or VEGFR-TKI/HIF-2i combinations in ccRCC Weiyu Zhang, Kathryn Bieging-Rolett, Ashley LaCayo, Ben Harrison, Jeremy Drees, Crissy Dudgeon, Nandita Bose, Eric S. Lightcap
• 6487 · PDF Exploratory study of camrelizumab combined with chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma Linlin Wang, Bingjie Fan, Bing Zou, Aiqin Gao, Shijiang Wang, Chunni Wang, Qian Shao, Yishan Yu, Hong Zhao, Jinzhi Wang, Yan Yi, Qingxi Yu
• 6488 · PDF Dual targeting of PARP and RAS enhances antitumor activity in pancreatic cancer Chani Stossel, Gali Altman, Dikla Atias, Yulia Glick Gorman, Hanita Ovadia, Liora Chouchan, Elina Haimov-Talmoud, Maria Raitses-Gurevich, Tamar Beller, Talia Golan
• 6489 · PDF Metabolic molecular subtyping of ovarian cancer reveals the role of oleic acid-CD36 in facilitating cisplatin resistance Jiagui Song
• 6490 · PDF MEK inhibition overcomes stromal-mediated resistance to a MERTK targeted therapy in AML co-cultures and vascularized mesenchymal organoids Chloe Hope, Katherine Minson, Eleana Vasileiadi, Madeline G. Higgins, Alejandro De Janon, Shuichi Takayama, Xiaodong Wang, Steven Frye, H. Shelton Earp, Douglas K. Graham, Deborah DeRykere
• 6491 · PDF Co-treatment with FAK and PARP inhibitors for the treatment of homologous recombination-proficient high grade serious ovarian cancer Caree Carson, Breana Hill, Aarya Ghosalkar, Marjaana Ojalill, Antonia Boyer, Xiao Lei Chen, David Schlaepfer, Dwayne Stupack
• 6492 · PDF Targeting phospholipase D1 overcomes platinum resistance and enhances cisplatin efficacy in ovarian cancer Shin-Wha Lee, Sung Wan Kang, Dong Woo Kang, Yu-na Noh, Young-Jae Lee, Min-Seo Lee, Yong-Man Kim
• 6493 · PDF Azvudine combined with Doxitinib, a potential therapy for EGFRm + NSCLC Jianmei Zhang, Shufang Zhang, Yujie Wang, Limin Jia, Ying Li, Pan Li, Feng Luo, Jinfa Du
• 6494 · PDF The selective YAP/TEAD inhibitor TY-1054 enhances the efficacy of KRAS inhibitors or Trop2-ADC in multiple solid tumors Shengli Dong, Zhengfei Guo, Zhiyong He, Apeng Liang, Meihua Li, Guangbin Liu, Chao Zhou, Yu Yu, Xinlong Yang, Hongqiang Li, Chengshan Niu, Shaoqing Chen, Jun Li, Yusheng Wu
• 6495 · PDF NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models Boback Kaghazchi, Enrique Podarosu, Asier Unciti-Broceta, Neil O. Carragher
• 6496 · PDF Methylseleninic acid enhances anti-FN14 CAR-T cell effector function and redirects cytotoxicity against TGF-beta-rich kidney, prostate, and brain tumors Gloria B. Kim, Obed B. Amissah, Casey R. Ager, Yousef Zakharia, Youcef M. Rustum
• 6497 · PDF Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimization Jaeger Moore, Taylor Bargenquast, Tithi Ghosh Halder, Serina Ng, Erkut Borazanci, Sara A. Byron, Cherie Wesley, Raffaella Soldi, Sunil Sharma
• 6498 · PDF Combination of MDM2 inhibitor and lipophilic gemcitabine: Strong synergism in lung cancer, while antagonism in brain cancer Bhoomi Mukeshbhai Dholariya, Akanksha S. Patel, Ketankumar Patel
• 6499 · PDF Targeting BCR-ABL1-independent mechanisms of resistance in chronic myeloid leukemia Mark Pusung, Christopher A. Eide, Jessica Gibbs, Daniel Bottomly, Haijiao Zhang, Brian J. Druker
• 6501 · PDF Preclinical evidence for synergistic activity of alectinib and everolimus in ALK-positive non-small cell lung cancer Hamadi Madhi, Habib Serhan, Rachel Mercer, Benjamin Levy, Anna Rottinghaus, Liwei Bao, Xu Cheng, Sharon R. Pine, Ross Camidge, Angel Qin, Nathan M. Merrill, Sofia D. Merajver, Matthew B. Soellner
• 6503 · PDF Investigating synergistic effects with CK2 and C-KIT inhibition in B-ALL Daniel Bogush, Stephanie Buczkowski, Rabab Husain, Sameer Ahmed Bhat, Yen Teng Tai, Avinash Kundadka Kudva, Sinisa Dovat
• 6505 · PDF Combination therapy with selective SMARCA2 (BRM) inhibitor HD-11273 for treatment of SMARCA4 (BRG1)-deficient cancers Hyuntae Kim, MinOu Choi, Jongwoo Park, Goeun Yang, Min-Ah Park, Hyo Sun Choi, Yukyung Kim, Doo-Young Kim, Daehoon Kim, Seong Heon Kim, Suk Ho Lee
• 6506 · PDF Antitumor synergy of AOH1996 and next-generation caPCNA Inhibitors in combination with targeted and chemotherapeutic agents Robert G. Lingeman, Long Gu, Caroline Li, Pouya Haratipour, Robert J. Hickey, Linda H. Malkas, Maryam Zangi
• 6507 Genomic characterization of lung cancer: ERRFI1 and NKX2-1 mutations and CLU expression Metamia Ciampricotti, Yingying Yu, Stamatina Fragkogianni, Jyoti Patel, Christine M. Lovly

在完整检索应用中浏览本分会场 →